Hereditary Pulmonary Alveolar Proteinosis Clinical Trial
Official title:
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
The purpose of this study is to evaluate the therapeutic efficacy of inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (PAP) due to partial dysfunction of the GM-CSF receptor.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05761899 -
Safety and Efficacy of PMT Therapy of hPAP
|
Phase 1/Phase 2 |